euro-obesity-euro-vaccines-2018-posters

Page 46

allied

academies

J u n e 2 8 - 2 9 , 2 0 1 8 | A m s t e r d a m , N e t h e r l a n d s

Joint Event on

OBESITY AND WEIGHT MANAGEMENT

VACCINES AND IMMUNOLOGY

International Conference on

Asian Journal of Biomedical and Pharmaceutical Sciences

Volume 8

ISSN:

2249-622X

Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C1-003

OUTCOME OF PREDNISOLONE TREATMENT OF IDIOPATHIC

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ADULT

PATIENTS IN OMDURMAN MILITARY HOSPITAL KHARTOUM

SUDAN

Altigani Aljafari

University of California, USA

Background:

Membranoproliferative glomerulonephritis (MPGN) is a type of glomerulonephritis caused by deposits in the kidney glo-

merular mesangial and basement membrane thickening, activating complement and damaging the glomeruli. (MPGN) classified to three

types according to location of deposits and based on etiology categorized to secondary and idiopathic.

Objective:

The aim of the study is to find the outcome of treatment (remission, partial remission, relapse and progress to end stage re-

nal disease) of idiopathic membranoproliferative glomerulonephritis, among adult Sudanese patients presenting to Omdurman Military

Hospital, Renal Unit.

Materials & Methods:

A retrospective study of patients with idiopathic MPGN followed up at the clinic. 45 patients with no identifiable

cause of MPGN were included. Idiopathic (MPGN) patients who have high renal profile or nephrotic range treated by three doses of meth-

ylprednisolone 0.5 g intravenous in three consecutive days and of corticosteroid tabs (0.5-1mg/kg/day), slowly withdrawn according to

the patient response indicated by spot urine test.

Results:

Out of 45 patients the following treatment outcomes were observed, (remission, partial remission, relapsed, and progressed to

(ESRD), (44%, 16%, 18% and 22%) respectively.

Conclusions:

In comparison to the similar studies, the remission rate is comparable, but the renal survival rate is different.